Incidental Monotypic (Fat-Poor) Renal Angiomyolipoma Diagnosed by Core Needle Biopsy by Kufer, Verena et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2012, Article ID 906924, 5 pages
doi:10.1155/2012/906924
Case Report
Incidental Monotypic (Fat-Poor) Renal Angiomyolipoma
Diagnosedby Core NeedleBiopsy
Verena Kufer,1 Siegfried A. Schwab,2 Maike B¨ uttner,1 Abbas Agaimy,1
Michael Uder,2 andKerstinAmann1
1Department of Pathology, University of Erlangen-N¨ urnberg, 91054 Erlangen, Germany
2Department of Radiology, University of Erlangen-N¨ urnberg, 91054 Erlangen, Germany
Correspondence should be addressed to Kerstin Amann, kerstin.amann@uk-erlangen.de
Received 12 December 2011; Accepted 6 February 2012
Academic Editor: Maxwell V. Meng
Copyright © 2012 Verena Kufer et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We present the case of a 55-year-old patient with a history of chemotherapy and bone marrow transplantation because of acute
myeloid leukaemia. An incidental 4 × 3cm measuring renal mass was detected while performing a magnetic resonance imaging
(MRI) for lumbago. The lesion was suspected to be either a renal cell carcinoma (RCC) or a leukemic inﬁltration. To decide about
further treatment a percutaneous core needle biopsy was performed. Histology showed a monotypic angiomyolipoma, a relatively
rare benign renal lesion. Interestingly, in cross-sectional imaging, angiomyolipoma was not taken into diﬀerential diagnostic
account because of lack of a fatty component. Due to bleeding after biopsy the feeding artery of the tumor was occluded by micro-
coils. This case demonstrates the utility of biopsy of renal tumors, in particular when small tumor-like lesions are incidentally
detected to decide about the right treatment and thereby avoiding nephrectomy.
1.Introduction
Due to advancements in modern imaging during the last
years, nowadays more than 70% of kidney tumours are de-
tectedincidentally[1].Inmostofthecasesappropriatetreat-
ment can be initiated on the basis of cross-sectional imaging
modalitieswithoutfurtherinvestigationsbecauseofthemass
showing certain signs of malignancy or coming up with pub-
lished imaging criteria of benign lesions like cysts or fat-
containingangiomyolipoma[2].Ifitisnotpossibletomakea
reliable diagnosis, percutaneous biopsy should be taken into
account to avoid unnecessary surgery.
Thepretestprobabilityofbenignlesionsisdeterminedby
tumor size: recent studies showed that up to 26.3% of small
(≤4cm) renal lesions and 16.8% of the masses >4cm are
benign [3]. Most frequently they are angiomyolipomas [4].
Angiomyolipoma belongs to the family of perivascular
epitheloid cell tumors (PEComa). In their classical form,
they present with a triphasic histology comprising variable
proportions of smooth muscle cells, thick-walled tortuous
blood vessels, and mature adipose tissue.
Immunohistochemically, the myogenic component
shows a variable expression of smooth muscle markers (sm-
actin, desmin or h-caldesmon) and melanocytic markers
(HMB-45 and Melan-A) [5].
The mean age of patients with angiomyolipoma is about
50 years and 78% of them are females [6]. Most angiomy-
olipomas are sporadic and rarely they do occur as part of the
tuberous sclerosis complex [7]. Both variants show alter-
ations involving the TSC gene [8].
2.CaseReport
Our patient, a 55-year-old woman, was diagnosed with acute
myeloid leukaemia and treated by allogenic stem cell trans-
plantation.
Developing lumbago a year later magnetic resonance
imaging (MRI) of the lumbar spine was performed. Along
withaninhomogeneoussignalintensityofthevertebralbone
marrow (which was attributed to the underlying acute my-
eloid leukaemia) and a spinal disc herniation at Th 8/92 Case Reports in Medicine
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Figure 1: (a–d) Axial MR images of the left kidney, T1-weighted in-phase (a) T1-weighted opposed phase (b) T2-weighted fat-saturated (c),
and T1-weighted, contrast-enhanced fat-saturated (d). The left renal mass is isointense in T1-weighted imaging without evidence of fatty
components(a,b);thesmallhypointensespotsinfat-saturatedT2-weightedimagingarevessels(c).ThemassishypointenseinT1-weighted
imaging after i.v. contrast media (d); solley centrally there are KM-enhancing foci representing vessels (d).
without relevant spinal stenosis, a 4 × 3cmmasslesionin
the lower pole of the left kidney was seen. The patient had no
stigmata of the tuberous sclerosis complex.
In a subsequent MRI of the kidneys the lesion was
classiﬁed as highly suspicious for RCC. As fatty tissue could
not be identiﬁed, an angiomyolipoma was not included in
the diﬀerential diagnosis (Figures 1(a)–1(d)).
It was decided to perform a percutaneous biopsy of the
renal tumor under computerized tomography (CT) guid-
ance. A 17G-coaxial biopsy needle was inserted into the tu-
mor under local anesthesia and three core needle biopsies
were taken.
Onhistologyrenalparenchymafromthecortexshowed8
glomeruli with a slight increase of mesangial cells and matrix
and ectatic tubuli (Figure 2(a)). Within the renal tissue there
were tumorous inﬁltrates composed of spindled and large
polygonal (polymorphic) tumor cells with hyperchromatic
andpartiallybizarrenuclei.Thetumorcellswerearrangedin
short irregular intersecting fascicles. The cytoplasm ranged
from eosinophilic and granular to clear with well-recogniz-
ablecellborders.Only1-2mitoses/10HPFcouldbedetected.
Inﬁltration of acute myeloid leukaemia could be excluded
histologically (Figures 2(b)-2(c)).
Immunohistochemistry was performed on 3µmp a r a ﬃn
sections using a polymer Kit purchased from Zytomed sys-
tems Ltd., Berlin, Germany according to the manufacturer’s
instructionsandDabasachromogen.Negativecontrolswere
used throughout. The renal tubular epithelial cells served as
endogenous negative control. The tumor cells were strongly
positive for smooth muscle actin (Figure 2(d)). Scattered
large tumor cells showed a strong granular cytoplasmic posi-
tivity for HMB-45 (Figure 2(e)) .T h et u m o rc e l l sw e r en e g a -
tive for pan-cytokeratin marker (KL-1), S100, renal cell
carcinoma marker RCC, CD10, and CD34. The proliferation
index assessed by MiB-1 was low (about 1%).
A control CT following biopsy procedure revealed a rele-
vant perirenal hemorrhage with active extravasation of con-
trast media. Subsequently, the bleeding artery was occluded
using microcoils. In the control angiography there was no
remaining extravasation, and the bleeding vessel was entirely
occluded.Onlastfollowup(25months),thepatientwasalive




Figure 2: Representative ﬁndings of the kidney biopsy (a) with the angiomyolipoma (b–e). (a) Light microscopy of the kidney, hematoxylin
stain (magniﬁcation ×4). (b) Light microscopy of the angiomyolipoma, hematoxylin stain (magniﬁcation ×100). (c) Higher magniﬁcation
of the tumor showed large spindled and epithelioid cells with clear and eosinophilic cytoplasm intimately associated with slit-like vascular
channels, (magniﬁcation ×400). (d) Immunohistochemistry using an antibody against actin (magniﬁcation ×100) shows a strong positivity
of the smooth muscle component of the tumor. (e) Immunohistochemistry using an antibody against HMB-45 (magniﬁcation ×100) shows
af e wp o s i t i v et u m o rc e l l s .
3. Discussion
The classic form of angiomyolipoma does not pose great
diagnostic diﬃculties on cross-sectional imaging relying on
the detection of macroscopic fat within a renal mass [9].
However, there are some angiomyolipomas that consist of
over95%ofonecomponentonly,forexample,adiposetissue
(lipomatous variant) or more often smooth muscle cells
(leiomyomatous variant) [6]. Tumors which contain less
than 25% fat, as in the current case (so-called “fat-poor
type”), present a diﬀerential diagnostic problem to radiol-
ogists so that most are suspected to be RCC on imaging.
Histological diagnosis of the classic variant of renal
angiomyolipoma is usually straight forward. To diﬀerentiate
angiomyolipoma from RCC sensitive and speciﬁc markers
are established nowadays [5].
The diﬀerential diagnosis of monotypic renal angiomy-
olipoma includes true smooth muscle tumors and RCC on
the one hand and liposarcoma on the other hand. The tumor
in the current case had a dominant smooth muscle com-
ponent that coexpressed both smooth muscle actin and
HMB45. The coexpression of these two markers (myome-
lanocytic proﬁle) is considered to be unique for angiomy-
olipoma and other members of the PEComa family, thus4 Case Reports in Medicine
ruling out the possibility of RCC or liposarcoma. Further-
more, the tumor showed a negative staining for CD10, RCC,
and KL-1, markers typically expressed in RCC. Particularly
in tumors with more pronounced HMB45 expression and
less prominent reactivity for myogenic markers, metastatic
malignant melanoma represents an important considera-
tion. Malignant melanoma may display cytomorphological
similarity to monotypic epithelioid angiomyolipoma, but it
usually shows features of frank malignancy and a more dif-
fuse and strong expression of HMB45 and protein S100 and
lack myogenic markers.
The nomenclature and biological assessment of renal
angiomyolipomahavebeencontroversial.Whilethepresence
of epithelioid areas within otherwise typical (triphasic)
tumors is generally considered of no signiﬁcance, evidence is
accumulating that purely epithelioid renal angiomyolipoma
(synonymously referred to as renal PEComa) may carry an
increased risk for malignant behaviour. In a recent study,
Nese et al. [10] analyzed a large series (n = 41) of well-char-
acterized pure (monotypic) epithelioid renal angiomyolipo-
mas (PEComas) for risk of tumor progression. They have
characterized associated tuberous sclerosis complex, concur-
rent angiomyolipoma in the kidney or other organ, tumor
necrosis,tumorsize>7cm,extrarenalextensionand/orrenal
vein involvement, and carcinoma-like growth pattern as
adverse clinicopathologic parameters associated with disease
progression. While tumors with <2 adverse prognostic para-
metersasinourcurrentcasewereconsideredtobeoflowrisk
for progression, those with ≥4 adverse prognostic param-
eters carried a high risk of progressive disease and most
have recurred or metastasized. These ﬁndings underline the
malignant potential of monotypic renal angiomyolipoma
(PEComa) thus necessitating surgical excision of larger tu-
mors that carries a signiﬁcant risk. However, that series was
biased by including mostly cases published previously or
selected for the study from more than 40 centers and by ex-
cluding cases with bland-looking histology. Accordingly,
most of analyzed cases had a remarkable or probably malig-
nant histology. This is evident from a mean tumor size of
1 1 . 9c mi nt h a ts t u d yw h i c hi sv e r yu n u s u a lf o ram a j o r i t yo f
renal angiomyolipoma [10, 11].
A deﬁnite preoperative diagnosis of a renal tumor is
pivotal due to the diﬀerent treatment strategies of RCC and
angiomyolipoma. While most small RCCs can be treated
with partial nephrectomy, and those in higher surgical risk
patients may be treated with less invasive modalities such as
cryoablation or RFA, thereby preserving renal function as
compared with radical nephrectomy for larger RCC, active
surveillance may be performed for patients with asymp-
tomatic angiomyolipoma, even in those with large tumors
[12]. The treatment of symptomatic (usually ﬂank pain) and
complicated (retroperitoneal hemorrhage) angiomyolipoma
comprises nephron-sparing surgery or selective arterial em-
bolization for angiomyolipoma smaller than 4cm [9, 13].
Several studies showed that tumor biopsy is an eﬀective
and safe approach to make a correct diagnosis of renal mas-
ses: the sensitivity of core needle biopsy is 70–100% with a
speciﬁcity of 100% and an accuracy of more than 90% [14,
15].
It has been shown that the highest sensitivity and the
highest negative predictive values (97% and 89%) are found
in masses between 4 and 6cm. They are lower in masses
smaller than 3cm (84% and 60%) and masses bigger than
6cm (87% and 44%) [16].
Possible reasons for false negative biopsies are sampling
errorsduetosmalllesions,whicharediﬃculttotargetorbio-
psies out of necrotic areas in larger tumors [14, 15]. There-
fore exact biopsy technique has to be performed to reduce
the risk of missing small lesions. Furthermore pre-bioptic
imaging has to be thoroughly analysed to diﬀerentiate be-
tween vital and necrotic components of renal masses.
As illustrated by our case the risk of a post interventional
haemorrhage has to be taken into account. Patients should
remain under observation after the procedure and follow-
up imaging should be performed if clinical symptoms of
haemorrhage are noted. However according to the literature
clinically signiﬁcant bleeding nowadays is considered to be
rare [15] and interventional radiologic occlusion of the
bleeding vessel(s) may be used for acute treatment as shown
in this case. Nevertheless it has to be mentioned that in case
ofa malignantdiagnosis (e.g.,RCC) in ourparticularpatient
the deﬁnitive treatment of the renal mass probably may have
needed to wait for hematoma resolution.
Therefore, if a tumor is diagnosed with conﬁdence on
cross-sectional imaging there is no need for percutaneous
biopsy. Biopsy should be performed, however, in diﬃcult to
classify renal masses, patients with extra renal primary tu-
mors,renalmassesthatmaybecausedbyinfection,consider-
ation for percutaneous ablation, and in unresectable patient
with comorbidity [17].
I nt h ep r e s e n tc a s ew ed e c i d e dt op e r f o r mC T - g u i d e d
renal biopsy because the tumor was diﬃcult to classify on
cross-sectional imaging, the patient’s history of leukaemia
with the possibility of recurrence and renal mass caused
by infection. Furthermore the tumor size of 4.0cm holds a
relativelyhighpercentofbenignmassesandahighsensitivity
and high speciﬁcity of renal biopsy.
In conclusion, this case illustrates the utility of needle
biopsy for evaluation of incidentally detected asymptomatic
small renal tumors. CT-guided biopsy is an eﬀective proce-
dure to make an accurate diagnosis and facilitate planning
of the appropriate treatment and can help to avoid more
aggressive surgical approaches and save patients’ kidneys.
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